Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Quercetin  COVID-19 treatment studies for Quercetin  C19 studies: Quercetin  Quercetin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Quercetin study #6   All Outcomes
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mortality 67% Imp. Relative Risk, 95% CI ICU admission 67% Hospitalization 67% Virological cure 74% Virological cure (b) 89% Di Pierro: Potential Clinical Benefits of Quercetin in the Early St.. c19quercetin.com/dipierro2.html Favors quercetin Favors control
6/24 Early treatment study
Di Pierro et al., International Journal of General Medicine, doi:10.2147/IJGM.S318949 (Peer Reviewed)
Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial
Source   PDF   Share   Tweet
RCT 42 outpatients in Pakistan, 21 treated with quercetin phytosome, showing faster viral clearance and lower symptom severity with treatment.
risk of death, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 21 (0.0%), control 1 of 21 (4.8%), relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of ICU admission, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 21 (0.0%), control 1 of 21 (4.8%), relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of hospitalization, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 21 (0.0%), control 1 of 21 (4.8%), relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of no virological cure, 73.7% lower, RR 0.26, p < 0.001, treatment 5 of 21 (23.8%), control 19 of 21 (90.5%), day 7.
risk of no virological cure, 88.9% lower, RR 0.11, p = 0.11, treatment 0 of 21 (0.0%), control 4 of 21 (19.0%), relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 14.
Di Pierro et al., 6/24/2021, Randomized Controlled Trial, Pakistan, South Asia, peer-reviewed, 12 authors.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
All Studies   All Outcomes
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Submit